✦ LIBER ✦

Analgesic effect of elcatonin in postmenopausal osteoporosis

✍ Scribed by J. Y. Reginster; J. Semler; C. Alexandre; J. J. Body; T. Appelboom

Publisher: Springer-Verlag
Year: 1996
Tongue: English
Weight: 155 KB
Volume: 6
Category: Article
ISSN: 0937-941X
DOI: 10.1007/bf02500533

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of elcatonin on involutional oste

Effect of elcatonin on involutional osteoporosis

✍ Hajime Orimo; Hirotoshi Morii; Tetsuo Inoue; Kichizo Yamamoto; Hiroshi Minaguchi 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 490 KB

Alendronate is more effective than elcat

Alendronate is more effective than elcatonin in improving pain and quality of life in postmenopausal women with osteoporosis

✍ J. Iwamoto; K. Makita; Y. Sato; T. Takeda; H. Matsumoto 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 158 KB

Analgesic effect of raloxifene on back a

Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis

✍ Takuo Fujita; Yoshio Fujii; Hiromi Munezane; Mutsumi Ohue; Yasuyuki Takagi 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 583 KB

A three-year comparative trial in osteop

A three-year comparative trial in osteoporosis treatment: Effect of combined alfacalcidol and elcatonin

✍ Takuo Fujita; Yoshio Fujii; Bunrei Goto; Akimitsu Miyauchi; Yasuyuki Takagi 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 288 KB

Slow-release NaF is clinically effective

Slow-release NaF is clinically effective in postmenopausal osteoporosis

✍ K. Sakhaee; V. Piziak; N. H. Bell; C. Johnston; C. Rubin 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 148 KB

Effects of denosumab on bone turnover ma

Effects of denosumab on bone turnover markers in postmenopausal osteoporosis

✍ Richard Eastell; Claus Christiansen; Andreas Grauer; Stepan Kutilek; Cesar Liban 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 272 KB 👁 1 views

## Abstract Denosumab, a fully human monoclonal antibody to RANKL, decreases bone remodeling, increases bone density, and reduces fracture risk. This study evaluates the time course and determinants of bone turnover marker (BTM) response during denosumab treatment, the percentage of denosumab‐treat